Profile data is unavailable for this security.
About the company
Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
- Revenue in USD (TTM)0.00
- Net income in USD-7.38m
- Incorporated2021
- Employees4.00
- LocationChromocell Therapeutics Corp685 Us Highway OneNORTH BRUNSWICK 08902United StatesUSA
- Phone+1 (917) 644-6313
- Fax+1 (302) 658-3694
- Websitehttps://chromocell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Templates Inc | 31.76m | -18.40m | 9.55m | 62.00 | -- | 1.33 | -- | 0.3006 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Weed Inc | 0.00 | -31.55k | 9.63m | 2.00 | -- | 37.73 | 337.48 | -- | -0.0002 | -0.0002 | 0.00 | 0.0021 | 0.00 | -- | -- | 0.00 | -2.49 | -385.93 | -14.84 | -822.37 | -- | -- | -- | -- | -- | -16.98 | 0.3488 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.36m | 9.68m | 3.00 | -- | 3.07 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Avalo Therapeutics Inc | 1.45m | -142.88m | 9.92m | 19.00 | -- | -- | -- | 6.84 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Chromocell Therapeutics Corp | 0.00 | -7.38m | 10.09m | 4.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -9,746.19 | -- | -- | -- | -- | -- | -- | -- | -- | -13.23 | -- | -- | -- | -- | -200.20 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.77m | -2.63m | 10.14m | 30.00 | -- | 1.05 | -- | 1.04 | -0.1389 | -0.1389 | 0.6873 | 0.5466 | 0.9703 | 7.98 | 5.33 | -- | -26.11 | -3.83 | -31.86 | -5.02 | 13.61 | 14.55 | -26.91 | -3.04 | 4.24 | -186.19 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Medical Marijuana Inc | -100.00bn | -100.00bn | 10.26m | -- | -- | 0.1104 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
| Vaxxinity Inc | 0.00 | -56.94m | 10.27m | 57.00 | -- | 0.7656 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| Oragenics Inc | 37.65k | -20.66m | 10.44m | 5.00 | -- | 4.56 | -- | 277.29 | -8.69 | -8.69 | 0.0167 | 1.03 | 0.0038 | -- | -- | 7,530.00 | -209.44 | -97.60 | -252.98 | -106.24 | -- | -- | -54,862.55 | -36,169.75 | -- | -- | 0.0898 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Galera Therapeutics Inc | 0.00 | -45.75m | 10.66m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Monopar Therapeutics Inc | 0.00 | -7.61m | 10.67m | 10.00 | -- | 1.43 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| BioCardia Inc | 477.00k | -11.57m | 10.70m | 16.00 | -- | -- | -- | 22.44 | -0.5525 | -0.5525 | 0.0225 | -0.0677 | 0.0747 | -- | 3.61 | 29,812.50 | -181.08 | -107.34 | -414.21 | -154.17 | -- | -- | -2,425.79 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
Data as of May 17 2024. Currency figures normalised to Chromocell Therapeutics Corp's reporting currency: US Dollar USD
9.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 3i Management LLCas of 21 Feb 2024 | 318.82k | 5.53% |
| Anson Funds Management LPas of 31 Mar 2024 | 251.89k | 4.37% |
| Certuity LLCas of 10 Apr 2024 | 0.00 | 0.00% |
Data from 31 Mar 2024 - 05 Apr 2024Source: FactSet Research Systems Inc.
